[5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia]

Zhonghua Xue Ye Xue Za Zhi. 2013 Jun;34(6):542-3. doi: 10.3760/cma.j.issn.0253-2727.2013.06.019.
[Article in Chinese]
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antimetabolites, Antineoplastic / administration & dosage*
  • Antimetabolites, Antineoplastic / therapeutic use
  • Azacitidine / administration & dosage
  • Azacitidine / analogs & derivatives*
  • Azacitidine / therapeutic use
  • Decitabine
  • Female
  • Humans
  • Karyotype
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / genetics
  • Treatment Outcome

Substances

  • Antimetabolites, Antineoplastic
  • Decitabine
  • Azacitidine